the pdf - Bladder Cancer Canada
Transcription
the pdf - Bladder Cancer Canada
A sponsored feature by Mediaplanet DECEMBER 2015 A RARE DISEASE The story of a thyroid cancer survivor. p04 INNOVATIVE TREATMENTS Nuclear medicine’s role in the fight against cancer. p06 BUILDING YOUR DEFENCE Activating the immune system to help beat cancer. p08 The Future of Cancer Care CANCERCARENEWS.CA Following the loss of both parents to cancer, actress Emmanuelle Chriqui vowed to help educate Canadians, sparking dialogue around the importance of testing. p09 ONLINE AT CANCERCARENEWS.CA Extended content from Emmanuelle Chriqui’s exclusive interview. THANK YOU CANADA! Together let’s continue to help end blood cancer. DONATE TODAY LIGHTTHENIGHT.CA 2 CANCERCARENEWS.CA A sponsored feature by Mediaplanet IN THIS ISSUE Comedian Brad Garret Shares his experience with cancer and palliative care. p07 Restoring hope Cutting edge treatments improving outcomes for liver cancer patients. p10 Improving quality of life The future of breast reconstruction surgery. p12 Canadian Researchers Play a Leading Role in Shaping the Future of Cancer Care Canada faces a 40 percent increase in cancer cases over the next 15 years, driven primarily by our aging demographics. C ancer is primarily a disease that affects older people and, by 2030, 1 in 4 Canadians will be at least 65. Incidence rates of cancer will remain relatively stable and survival rates will continue to climb across most types of cancers. Prostate, lung, colorectal, and breast cancer will continue to be the most common. Some cancers, such as prostate, are strongly associated with older age, but others, including thyroid cancer and multiple myeloma, will see an increase due to better diagnostic technologies and practices. A rise in liver cancer cases will be fueled by the high number of Canadians with hepatitis, as well as obesity. New areas of research The need to invest in cancer research has never been more urgent. Canadian researchers are playing a big role in changing the future of treatment by embracing new areas of research in cancer biology. For instance, a group of researchers in Ottawa are developing a new method that treats cancer with viruses. They engineer special oncolytic viruses that target cancer cells selectively while leaving normal cells unharmed, greatly reducing side effects. Dr. John Bell, a world leader in this field, genetically tailors viruses to thwart a cancer cell’s ability to defend itself against viruses. His work is particularly promising for aggressive, hard-to-treat cancers such as pancreatic. Dr. Jean-Simon Diallo and Dr. Rebecca Auer, also in this group, use viruses to make cancer cells more responsive to treatment, and to activate the immune system to prevent cancer from spreading. Targeted therapies Dr. Katie Wright Senior Manager, Research Communications Canadian Cancer Society, Ontario Division “Canada can play a leading role in shaping the future of treatment.” Biologics are another area of research with great potential. Biologics are a targeted type of therapy that uses synthetic antibodies to mimic the immune system’s own ability to attack proteins on the surface of cancer cells. The new Toronto Recombinant Antibody Centre was set up to enable rapid development of these biologics. Dr. Bradly Wouters, for example, is designing biologics that hinder a cancer cell’s ability to grow and divide by interfering with its metabolism. These new therapies have the potential to be effective for patients with different types of cancer, including aggressive forms, while being less toxic to patients. Focused therapies are the key to both successful treatment and greatly reduced side effects. The BC Cancer Agency supports a clinical trial for the Personalized Oncogenomics Program of British Col- umbia, which is interested in treating cancer patients with “personalized” medicine. The investigators assess a patient’s individual cancer using genome sequencing to identify what genes are causing the cancer to grow and thrive and, if possible, match the patient to a biologically relevant targeted therapy. While still a pilot project, investigators have shown this approach is feasible and produces some promising patient outcomes. Canada’s role Canada can play a leading role in shaping the future of treatment. We have some of the world’s leading innovators in cancer research, including prevention, treatment, early detection, and palliative care. They need and deserve support. I urge you to get involved in the fight against cancer by supporting charities that fund cancer research in Canada. Progress in Treatment of Blood Cancers White blood cells protect us from infection. However, these cells can become cancerous, leading to malignancies including leukemia, lymphoma, and myeloma. Just 50 years ago, a diagnosis of one of these blood cancers was usually a rapid death-sentence. We understood very little about how these cancers developed and there were essentially no effective treatments. Dramatic scientific breakthroughs in the past several years have significantly improved our understanding of these diseases and have opened up new treatment opportunities. New advances in the genetic analysis of cancer cells allow physicians Stay in Touch and scientists to pinpoint the molecular defects in a patient’s blood cancer cells. These molecular mutations let physicians better predict the likely response to treatment and personalize the treatment approach. In addition, new drugs targeting these specific mutations in blood cancer cells have been developed and are being tested in clinical trials. Some of these drugs are producing dramatic responses in patients who are resistant to conventional chemotherapy. We are also learning about the origins of blood cancers such as leukemia — for example, why and how some cancers relapse after initial treatment. This knowledge is also opening up new possibilities for facebook.com/MediaplanetCA treatments and how to monitor patients during and after therapy. Immunology Recent breakthroughs in immunology have revealed new opportunities for the treatment of blood cancers. Antibodies that preferentially target blood cancer cells are currently used to treat many patients both as standard of care and in clinical trials. We are also learning how to harness the patient’s own immune system to treat cancers. In patients with solid tumors such as lung cancer, new drugs can prompt the patient’s immune cells to recognize and destroy the cancer. Clinical trials with these agents are on-going in blood cancers. Finally, in the last few years, we have been able to @MediaplanetCA @MediaplanetCA genetically modify a patient’s immune T cells so they can better recognize the blood cancer within them. These modified cells are then infused back into the patient where they seek out and attack the blood cancer. Dramatic results have been seen with this experimental therapy and studies evaluating the effectiveness and safety of these cellular therapies are on-going. Improved patient journey Coupled with the advances in molecular biology and new drug therapy, we are also improving our ability to support patients through their journey with cancer. Interventions to address the symptoms of cancer and the side effects of treatment such as pain, fatigue, depression, and propinterest.com/MediaplanetCA blems with memory are being intensively studied. Improvements in our support for patients and their families will be critical as it will allow them to live better as well as longer. Thus, we have seen remarkable progress in the last 50 years in the scientific understanding of how blood cancers develop and why they return in some patients after initial treatment. As a result, scientific progress is now being translated into improved therapies for our patients. By Aaron D. Schimmer, Staff Physician and Senior Scientist, Princess Margaret Cancer Centre, University Health Network Please recycle after reading Publisher: Samantha Blandford Business Developer: Ian Solnick Managing Director: Martin Kocandrle Production Manager: Carlo Ammendolia Lead Designer: Matthew Senra Contributors: Dr. Katie Wright, Aaron Schimmer, Stephen Wilson, Amy Elmaleh, Ishani Nath, Ben Chacon, Ken Donohue, Sandra MacGregor, Randi Druzin, Duff McCourt Cover Photo: Roberto Aguilar Photo credits: All images are from Getty Images unless otherwise accredited. Send all inquiries to ca.editorial@mediaplanet.com This section was created by Mediaplanet and did not involve Toronto Star or its Editorial Departments. MEDIAPLANET 3 A sponsored feature by Mediaplanet INSIGHT The Hidden Cancer with a Big Impact F or a cancer that most people have never heard of, it may surprise readers to discover that bladder cancer is the 5th most common cancer in Canada — fourth among men and twelfth among women. There are an estimated 80,000 bladder cancer patients in Canada — about 8,300 more are diagnosed every year and 2,300 will die of the disease. Bladder cancer is the most expensive cancer to treat on a per patient basis because of an 80 percent recurrence rate. Yet, ranking 20 out of the 24 most common cancers, research funding into this disease lags almost all other cancers. Although the exact cause of bladder cancer is not known, smoking is a common risk factor, as is age and occupational exposure to specific chemicals. The most common symptom of bladder cancer is blood in the urine (called hematuria). Bloody urine may vary from pale yellow-red to bright or rusty red. Blood in the urine does not always indicate bladder cancer — it can be caused by a number of conditions — but seeing a doctor immediately to find out is critical. Early diagnosis can increase the chances of effective treatment. Other symptoms may include bladder spasms, increased frequency and urgency of urination, and burning sensation during urination. “Bladder cancer is the most expensive cancer to treat on a per patient basis because of an 80 percent recurrence rate.” In about 80 percent of cases, bladder cancer tumours are contained within the bladder and have not grown into the surrounding muscle or beyond (nonmuscle-invasive disease). This type of bladder cancer is initially treated with surgery to remove the tumours from inside the bladder and patients may require additional drugs placed into the bladder. When the tumours have grown into the muscle of the bladder or spread beyond into other tissues, organs, or lymph nodes (muscle-invasive disease), treatment may include chemotherapy, surgery, radiation, or a combination of these — depending on how far the tumour has spread. Surgery usually involves removal of the entire bladder (radical cystectomy). When the bladder is removed, a segment of bowel is used to allow drainage of the urine. Select patients may be treated with chemotherapy or radiation, instead of surgery. By Stephen Wilson, Director & Communications Chair, Bladder Cancer Canada Susan Marshall and son share a warm embrace. Photo: Submitted Putting Our Heads Together To Fight Brain Cancer When Susan Marshall’s son, Brent, was just four years old, she heard the words no parent should ever have to hear — “Your child has a brain tumour.” Despite the devastating news, Brent underwent surgery, radiation, and chemotherapy, responding well to the treatments. He led a full life into adulthood, went to college, and worked in a computer lab,” says Marshall, CEO of Brain Tumour Foundation of Canada. “But an aggressive form of the cancer returned when Brent was 23. He died less than a year later.” Why brain cancer is difficult to diagnose Of the two types of brain tumours — benign and malignant — benign is more common; however, malignant tumours are largely incurable with brain cancer being the leading cause of cancer death in people under 20. Early detection is important, but this can be challenging, because brain cancer is a complex disease. “One of the difficulties is that brain cancer is rarer than other forms of cancer, and we don’t see a lot of cases,” says Dr. Arjun Sahgal, a Radiation Oncologist at Sunnybrook Hospital. “The symptoms — headaches, numbness in the face, vision impairment, seizures — can also mi- mic other conditions and sometimes they don’t get picked up early.” Research is improving quality of life While the treatment for brain tumours is complex, there have been positive advances. Traditionally, brain tumours were only treated with radiation, but research has shown that combining radiation with chemotherapy has better outcomes. “Part of the reason we can now better adapt treatment is that we have a better understanding of the genetic profile of the tumour,” says Dr. Sahgal. “Research is reshaping our understanding, and we are rethinking how we treat brain cancer. Even some people with malignant tumours are living 10 and 20 years longer.” While clinicians are still searching for the next breakthrough, there is a new suite of drugs being developed that will help to shut tumours down, and researchers are looking at how they can activate a patient’s immune system to attack the cancer. “Our hope is that brain cancer will become more of a chronic and managed disease, and not a death sentence,” says Marshall. “With continued research, we can get there. It’s that hope for other families that keeps us going.” By Ken Donohue Every day across Canada, 27 people learn they have a brain tumour. But there is Hope. At Brain Tumour Foundation of Canada, volunteers and staff work to provide specialized community programs to patients and caregivers impacted by this disease. We also fund ground-breaking research to find the cause of and cure for brain tumours. Join the movement to end brain tumours today. Give, Advocate, Volunteer. 1-800-265-5106 www.braintumour.ca Charitable Registration #BN118816339RR0001 4 CANCERCARENEWS.CA A sponsored feature by Mediaplanet INSIGHT A Survivor’s Story: One Woman’s Battle with Thyroid Cancer Melissa Salvatore, board member at Thyroid Cancer Canada, enjoys the outdoors with her husband. Photo: Submitted By Sandra MacGregor At the age of 29, Melissa Salvatore, thought she had it all. Grateful for a fulfilling job and a wonderful husband, she was looking forward to the future and had even planned to speak to her doctor about family planning. I n March of 2013, Melissa was undergoing her annual physical when her doctor paused a long time on her neck and then asked, “How long has your neck been so swollen?” Things moved very quickly from there. Within a few weeks, Melissa had an ultrasound and a CT. The scans showed a nodule almost eight centimetres large. A biopsy revealed the mass was papillary thyroid cancer. Though papillary is generally considered the most treatable form of thyroid cancer, Melissa’s was more serious because it had moved into her lymph nodes. “At the time I knew nothing about thyroid cancer. I knew I had a thyroid but didn’t really know what it did. We are told to check our skin for moles or for lumps in our breasts but no one ever talks about checking your neck.” Self-education is key Melissa dealt with her shock and confusion by researching her condition. “There was not much information nodes and the entire thyroid gland. The involvement of the lymph nodes made the surgery more invasive and for a long time I had lin- “One of the most important things I did was educate myself. It helped me feel more in control of a very uncontrollable journey.” out there but I did find Thyroid Cancer Canada,” she recalls. “Their website is great. I will always say that one of the most important things I did was educate myself. It helped me feel more in control of a very uncontrollable journey.” Melissa was scheduled for surgery in May. “My surgery was very invasive. They took out forty lymph gering pain.” Yet already her cancer was beginning to teach her to look at life differently. “I had my thirtieth birthday a couple of weeks later. I remember others complaining about how old they felt, and feeling impatient with them. We should be grateful for every year we are able to celebrate.” Radioactive iodine and isolation Unlike most cancers, thyroid cancer patients take radioactive iodine to treat their disease. They are kept in isolation for three days to ensure that they don’t endanger others with their body’s radioactivity. After surgery, Melissa’s radioactive iodine treatment left her feeling even more afraid and isolated. “Our house was small and my husband couldn’t even stay with me during the treatment. He had to stay with my parents for the three days to prevent harm from my radioactivity.” Sadly, Melissa and her family had more challenges to face. “I thought things were as bad as they could be but everything got a whole lot worse,” she explains. “After the radioactive iodine I went for a full body scan to see how I was doing and I lit up like a Christmas tree. The scan showed the cancer had metastasized to my lungs. Having cancer at twenty-nine was one thing, but then to learn I had metastatic cancer at thirty shook me to my core.” A positive outcome A few months later, Melissa did another round of radioactive iodine and the results were much more positive: the cancer in her lungs appeared to be gone. “It completely exceeded my physician’s expectations,” enthuses Melissa. Though she will have to be on hormone replacement medication for the rest of her life and under a physician’s supervision, Melissa has not required any additional treatment for the last two years and has been feeling great. “Having thyroid cancer really changed my life. I feel more grounded and have a perspective that I wouldn’t have had otherwise. Having cancer as a young woman was very hard but it’s given me wisdom and maturity that I wouldn’t have had otherwise. I see life very differently now and try to live each moment to the fullest.” Thyroid Cancer: A Rare but Unwelcome Disease At a time when the general public is more well-informed about cancer than ever before, thyroid cancer remains an unclear and misunderstood disease. There is little known about its causes or how to prevent it. It’s also unique in that treatment for the disease rarely involves chemotherapy or radiation, but rather requires surgery in which the thyroid gland is partially or completely removed, followed by a dosing of radioactive iodine. Patients are required to ingest the substance and then endure three days of isolation in order to ensure they don’t endanger others with their body’s radioactivity. Little awareness “There is very little awareness about thyroid cancer,” explains Rita Banach, a thyroid cancer survivor and one of the founders of Thyroid Cancer Canada. “I think that’s because it’s still a relatively rare cancer and it’s also seen as very curable.” While it has traditionally been more uncommon, the rate of thyroid cancer is increasing every year, faster than any other cancer. Over 6,300 people will be diagnosed in 2015 — up from 3,400 a decade ago. Over half of people living with thyroid cancer are between the ages of 15 and 49, and almost 80 percent of them are women. Yet despite the alarming incidence of the cancer among young women it remains very much under the radar. When caught early, it can be very treatable. But, the potential seriousness of thyroid cancer cannot be easily dismissed. “Although most people have the curable form of thyroid cancer, there’s a small percentage that have a very dangerous type and Hormone replacement therapy Participants at the thyroid cancer awareness run. Photo: Submitted “It’s often detected almost by accident. People may be having an ultrasound for an unrelated condition and a nodule in the neck is detected.” they often don’t live longer than five months,” says Banach. Unique diagnosis and treatment What also makes thyroid cancer so unique is the way it’s diagnosed, explains Dr. Alice Cheng, an endocrinologist at Credit Valley Hospital and St. Michael’s Hospital, and a member of the Medical Advisory Panel for Thyroid Cancer Canada. “It’s often detected almost by accident. People may be having an ultrasound for an unrelated condition and a nodule in the neck is detected. Or, a person feels a bump when they apply face cream, or you notice a lump in a friend’s neck.” Afterwards, as the thyroid is an essential gland that regulates metabolism among other body functions, patients must receive hormone replacement therapy for the rest of their lives. Unfortunately, there is no standard dosage and the amount needed varies widely between individuals. Until the correct amount is attained, which can take months, patients can experience the following symptoms: fatigue, depression, weight gain, and an overall sense of poor well-being. High recurrence rate Thyroid cancer survivors also have a lifetime of medical monitoring ahead. “Thyroid cancer has a very high recurrence rate — up to thirty percent,” says Banach. “So unlike other cancers where the patient may be followed for a few years, we are monitored for the rest of our lives. With thyroid cancer we don’t ever use the word remission; we just say there is presently no evidence of the disease.” Patients are often told by their doctors that they have “the good cancer” — but that does little to help with the fear, anxiety, and worry that so many people experience when they receive a thyroid cancer diagnosis. While raising awareness about thyroid cancer is essential, Dr. Cheng emphasizes that certain people may be at higher risk. “People with a family history or who have had exposure to severe radiation (not like that from dental X-rays or a CT scan) should have their thyroid checked. But in general, most nodules are benign.” Like a chronic disease But the rare nature and low fatality of the disease does not mean that those who are afflicted are immune from the fears and stress that any cancer patient endures. “We need emotional support,” insists Banach. “Having thyroid cancer is like living with a chronic disease. Once you’ve been diagnosed you have to take hormone replacement pills and be monitored for the rest of your life. We are not just statistics; we are people, and having cancer, no matter what kind, is scary.” By Sandra MacGregor A Commitment to Thyroid Cancer Patients This section is made possible by support from Genzyme Canada MEDIAPLANET 5 A sponsored feature by Mediaplanet The thyroid gland is a butterfly-shaped organ at the base of your neck. It is a vital organ that produces hormones that help to regulate your metabolism. It also works to help the functions of your brain, lungs and heart. Thyroid Cancer: Know the Facts The rate of thyroid cancer is increasing every year, faster than any other cancer In 2015, over 6,300 Canadians will receive a thyroid cancer diagnosis Almost 80% of those who are diagnosed are women Half of those who are diagnosed are between the ages of 15 and 45 years old Take Back Control There are many things you can do to help you feel more in control of how your cancer is managed • Make a list of questions before you go to your appointment. • Ask family or a friend to come with you to take notes for you. • Track your symptoms and sideeffects. What does it keep you from doing? What makes it better? Worse? • Bring a calendar and note when you can expect to be contacted for referrals and appointments. • Ask for copies of lab reports • Ask when you will see your doctor again, and how to reach him or her if you have questions. Thyroid Cancer Canada supports patients and their families as they make important decisions about their health. Questions? We can help. ThyroidCancerCanada.org ThyroidCancerCanada ThyroidCancerCa 6 CANCERCARENEWS.CA A sponsored feature by Mediaplanet EXPERT OPINION Nuclear Medicine and Cancer Care: What You Need to Know Dr. Christopher O’Brien explains why you should not be scared of nuclear medicine and how it makes a big difference in cancer care. W hile some may associate nuclear technology with clean energy or weaponry, this field has also been at the forefront of molecular medicine or personalized medicine leading to significant clinical advances — specifically in the fight against cancer. Nuclear medicine has become an important tool for cancer detection and treatment, as well as alleviating cancer-related pain in palliative care, explains Dr. Christopher O’Brien, Chief of Nuclear Medicine for the Brant Community Healthcare System. “In select populations, this is a very powerful tool that helps treat the patients more effectively and in a more balanced way.” Catching cancer earlier Before cancer can be treated, it must be accurately detected. Medical imaging such as CT scans, MRIs and X-rays show what’s beyond the skin’s surface, but nuclear medicine adds a new perspective. “MRI and CT scans look at the structure and anatomy of what an organ actually looks like,” says Dr. O’Brien. “What nuclear medicine is actually looking at, is the cellular function.” Nuclear imaging involves the patient swallowing, inhaling or being injected with a radiopharmaceutical — a drug comprised of a pharmaceutical agent targeted at a specific organ or tissue as well as a material that gives off small amounts of radiation. According to the Canadian Cancer Society, areas that contain tumours will “take up” the pharmaceutical in an abnormal way. The radiation acts as a marker, bringing potentially cancerous tumours to the physicians’ attention. “Nuclear medicine looks at cellular and tissue activity, allowing us to detect disease entities earlier on, before the organ actually changes shape,” says Dr. O’Brien. According to O’Brien, adding nuclear imaging to the arsenal of cancer-detecting tools can lead to a more accurate picture of a patient’s condition — allowing doctors to see if a cancer has spread or assess if treatment is working. “You need the anatomic assessment and you need the functioning assessment to be able to plan your best treatment more effectively,” he says. “The radioactive iodine will be picked up by the residual cancer cells that may be there and that will kill off those cells,” says Dr. O’Brien. “The same thing occurs if the cancer has spread to the lungs or other “In select populations, nuclear medicine is a very powerful tool that helps treat patients more effectively.” Treatment and pain relief Once diagnosed, nuclear medicine can also provide patients with additional treatment for cancer, particularly for those with thyroid cancer or specific types of adrenal gland, neuroendocrine or blood cell tumours. Nuclear medicine uses radioactive isotopes specifically targeted to an area of the body — such as radioactive iodine used to combat thyroid cancer — to destroy cancerous cells. parts of the body or in the bone; the cancer is still picking up the radioactive iodine and is able to be treated that way. This therapy complements surgery, for instance, and together they minimize the chances of the disease coming back.” When cancer causes pain, such as when it has migrated into a patient’s bones, nuclear medicine can also be used to target and kill the cancerous cells, thereby alleviating some of the patient’s discomfort — often with minimal side effects. “As we’ve become more familiar with the treatment options, we’ve found that many more people can access medical isotope treatment without any complications and the reason for that is that it’s targeted therapy, it’s not affecting the whole body,” says Dr. O’Brien. The Canadian Cancer Society estimates that 196,900 new cases of cancer will be diagnosed this year. For some of these patients, nuclear medicine can make a difference in how their disease is understood and treated. “[Nuclear medicine is] something a patient should not be afraid of because of the name,” says Dr. O’Brien. “It’s very important to have a discussion with your doctor to see if therapy with radiopharmaceuticals would be beneficial for your type of cancer.” By Ishani Nath Radioiodine Ablation in Differentiated Thyroid Cancer One Mission. Remission. The standard of care—backed by decades of clinical success1 >96% 10-year survival rate*2 85% of differentiated thyroid cancer patients receive radioiodine ablation †3 “Re-sets” the risk of recurrence3 Patients classified as high-risk had the same recurrence rate as low-risk patients after successful I-131 ablation2 Recurrence-free survival in high-risk and low-risk patients (P=0.68) 1.0 Recurrence-free Survival Rate “Successful ablation is a positive predictor of a highly favorable prognosis…support[ing] the continuation of adjuvant radioiodine.”2 .8 Risk Group .2 Low-risk High-risk .0 0 5 10 15 20 Recurrence-free Survival (Years) 25 The administered ablation doses ranged from 1,100 MBq I-131 in patients with large thyroid remnants to 7,400 MBq in patients with extensive locally invasive or metastatic disease2 *Standard treatment of total thyroidectomy followed by radioiodine ablation. † 30 Based on Verburg et al, 2010.2 Based on the results of a large, multinational, patient/survivor-initiated survey of 2398 participants. www.draximage.com References: 1. Siegal E. The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of Samuel M. Seidlin, MD (1895-1955) and his celebrated patient. Ca Biother & Radiopharm. 1999;14(2):71–79. 2. Verburg FA, Stokkel MPM, Duren C, et al. No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:276–283. 3. Banach R, Bartès B, Farnell K, et al. Results of the Thyroid Cancer Alliance international patient/survivor survey: Psychosocial/ informational support needs, treatment side effects and international differences in care. Hormones. 2013;12(3):428–438. MEDIAPLANET 7 A sponsored feature by Mediaplanet INSPIRATION Leaving with Love The Difference Palliative Care Makes Acting may be his profession, but comedian Brad Garrett says his “calling” is bettering cancer and end-of-life care — issues that are close to his heart. By Ishani Nath “I lost my best friend — we were literally like brothers — and I lost my father and my biological brother, all within a three year period, to cancer,” says Garrett, best known for his role as Ray Romano’s brother on Everybody Loves Raymond. According to the Canadian Cancer Society, cancer is the nation’s leading cause of death. Nearly half of all Canadians will develop cancer in their lifetime and a quarter will die from the disease. Facing death is a universal fear, but end-of-life care, also known as palliative care, is designed to make the most of a patient’s final days. “There was so much dignity,” says Garrett, remembering his friend’s final days at a Nevada hospice. “So much love and care that my friend was surrounded with.” Surrounded by angels Palliative care and hospice staff work to ease patients and their loved ones through an unthinkably difficult time. “They all just seem to have a real strength,” says Garrett. “A strength that makes the patient feel protected, so that these poor people who are facing their last days feel that someone has their back beyond their family, beyond their loved ones. You need that medical staff that really makes you feel that you’re going to go out the best way you can.” In Canada, hospice palliative care programs aim to give patients more control over their remaining life, manage symptoms and pain, and provide support to those they leave behind. “They’re really like angels,” says Garrett. A helping hand When Garrett and his wife welcomed new life into their family, it inspired him to help the families of children with lifelimiting illnesses. “When I was lucky enough to have two healthy kids, I said to myself, I’ve got to do something where I can help these families because there’s nothing more frightening than losing a child or having a child who is ill,” says Garrett. The actor started the Maximum Hope Foundation, a non-profit organization named after his children Max and Hope, that helps nearly 150 families per year with daily necessities – everything from mortgage payments to car repairs, to groceries. When Garrett later experienced end-oflife care alongside his loved ones, he was further inspired to help. “Through the care that I’ve received for my friends and family, I just felt that going with dignity, without the pain, the best way that the country will allow their patients to go, was something that I wanted to be involved in,” says the palliative care advocate. After what he’s witnessed through his foundation and with his loved ones, Garrett says that in the end, it comes down to celebrating the life of each patient. “It sounds corny, but you’ve really got to celebrate the life, the memory, and what they left when they were here,” he says. Ottawa Mother’s Story Shows Breast Screening Saves Lives Geety MacLean’s first thought when she got the results of a breast biopsy was, “What will happen to my two kids if I die?” The Ottawa mother wondered if she had just been handed a death sentence. Invasive cancer In the following weeks, the news went from bad to worse. Further tests revealed that the cancer had spread across one of her breasts and it had to be removed. Following surgery, a pathology report revealed the cancer was invasive and had spread to her lymph nodes. MacLean, who was a senior product manager with a high tech company, endured four months of chemotherapy and another month of radiation before starting on medication that interferes with the growth and spread of cancer cells. The next year, her ovaries and fallopian tubes were removed as a precautionary measure. Today, almost nine years later, she is healthy. Screening saves lives MacLean says she owes her life to breast screening. If not for the mammogram that raised a red flag, which she had requested at the urging of a colleague, Maclean wouldn’t have discovered she had cancer until much later — and it might have been too late. MacLean, who was 46 years old at the time, was feeling fine and had no inkling anything was wrong. Many Canadian women have similar stories, says radiologist Jean Seely, who is an active member of the Canadian Association of Radiologists (CAR) Breast Imaging Working Group and the Head of Breast Imaging at the Women’s Breast Health Centre in Ottawa Hospital. “Often, when I tell a woman she has breast cancer, she is blown away. She says, ‘I eat well and I exercise regularly. There is no history of breast cancer in my family. How could this happen?’ But unfortunately, it does happen.” Seely says that 75 percent of women who are diagnosed with breast cancer have no risk factors at all. “75 percent of women who are diagnosed with breast cancer have no risk factors at all.” Screening is key She stands by the CAR guidelines and recommends screening for women 40 years and older — breast cancer rates are dramatically lower among younger women — and dismisses claims that screening with mammography doesn’t reduce the number of women who die from breast cancer. Seely points to a Canadian study published in the Journal of the National Cancer Institute in October 2014 that car-ad-BreastAdvice-e-2015-print-v1.pdf 1 2015-11-03 1:03 PM OUR BRE BREAST BR EAST AD A ADVICE DVICE ON AN IMPORT IMPORTANT RTANT RT TANT DISCUSSION WITH YO Y UR PHYSICIA Y YSICIA N YOUR PHYSICIAN An important decision, such as when to undergo breast cancer screening, is best made after an informed discussion with your physician. Starting at age 40, all women are urged to speak with their physician about beginning regular breast screening*. determined breast cancer screening reduces mortality rates by 40 percent in all women, and by 44 percent in women aged 40-49 years. Seely also notes that it’s easier to get screened than most people realize. A woman doesn’t always need a physician’s referral to get a mammogram. Once she is in the Ontario Breast Screening Program — which provides screening to all women in the province between the ages of 50 and 74 — she can selfrefer. Women 40-49 years old require a referral from a family physician. Other provincial screening programs have similar processes in place, although details vary among provinces. You are your own advocate In Ontario, women in the program get screened every one to two years unless they are considered high risk. In that case they get a mammogram and breast MRI annually. “Simply put, breast screening saves lives,” says Seely. No one is more convinced of that than MacLean. “I urge every woman to be her own advocate. Know what screening tests are available to you and ask about them,” she says. “Because anything can happen to anyone.” By Randi Druzin A FEATURE BY LUNG CANCER PATIENTS AND CAREGIVERS FACE AN OVERPOWERING AVALANCHE OF INEQUITIES Lung Cancer Canada’s Faces of Lung Cancer: One Patient, One Diagnosis, Countless Casualties is an in-depth look at lung cancer in Canada and uses the results of the 2015 patient and caregiver survey to give voice to the human toll of this disease. Providing new perspectives on the country’s deadliest cancer, the report speaks to a virtual avalanche that devastates and impacts countless lives and systems in its path. In a disease with low survival rates, we are at risk of failing patients and caregivers due to obstacles preventing access to lifeprolonging treatment, limited research investment, inadequate availability of local support services, as well as a concerning lack of compassion for patients and caregivers living with the disease. The inequities start even before diagnosis. Depending on where a patient lives, it can impact how quickly they are diagnosed, the support they can access, and how long it will take to see a specialist and receive treatment. Caregivers are key soldiers in a patient’s fight but this comes at a high cost. Fifty nine percent of caregivers reduce the number of hours they work, and a further 8 percent quit their jobs to look after a loved one with lung cancer. Fifty percent of caregivers reported a negative impact on their household finances. When asked what would make caregiving easier to manage, caregivers most often mention greater empathy towards lung cancer in general and better access to support services. However, the survey showed that only 26 percent of caregivers have ever received these services. Even when they are offered, wait times and access points can differ between provinces, regions, and cities. The deep-seated perception that lung cancer is self-inflicted places an additional burden on families. This negative stigma prevails despite the fact that the majority of Canadian lung cancer patients are exsmokers, and many never smoked at all. Although lung cancer has the highest mortality of all cancers in Canada, it receives a disproportionate amount of research investment compared with both the scope of the cancer and with other cancers. In fact, as of 2012, significantly more funds were going into research for breast cancer and prostate cancer. While it is important that research continue in these cancers, it is also important to acknowledge the obvious need for more investment in lung cancer research that, at the very least, matches the significant burden of disease. Indeed lung cancer kills more Canadians a year than breast cancer, prostate cancer, and colorectal cancers combined. As outlined in the report, lung cancer patients and their caregivers continue to face a number of significant challenges. Lung Cancer Canada urges all Canadians to step-up and advocate for everyone who suffers from lung cancer and help create the necessary change. For more information on lung cancer and to view a copy of the Faces of Lung Cancer report, please visit: www.lungcancercanada.ca. BREAST CANCER SCREENING KNOW YOUR RISKS Whether you are at average or high risk for breast cancer is determined from a number of factors, such as: • a personal or family history of breast and/or ovarian cancer; • dense breasts; • a woman's reproductive history; • exposure to ionizing radiation; • use of hormone replacement therapy; • some lifestyle factors, such as obesity; • and other potential factors as determined by your physician. *The Canadian Association of Radiologists (CAR) has a series of guidelines on breast imaging compiled in the CAR Practice Guidelines and Technical Standards for Breast Imaging and Intervention. The CAR is the national voice of radiologists. As specialized physicians who are part of your healthcare team, our commitment is to promote patient safety in medical imaging. TALK ABOUT YOUR RISK FACTORS WITH YOUR PHYSICIAN. MAKE A DECISION THAT FEELS RIGHT FOR YOU. 613 860-3111 info@car.ca www.car.ca 8 CANCERCARENEWS.CA A sponsored feature by Mediaplanet INSIGHT Using the Body’s Natural Defence System to Battle Cancer In the fight against cancer, the leading cause of death in Canada, research indicates that for some patients the human body may be its own greatest weapon. I By Ishani Nath mmuno-oncology, also known as immunotherapy or biological therapy, is a relatively new treatment that uses the body’s immune system to fight cancerous cells. “Cancer cells can manipulate the immune system and make it ineffective,” explains Dr. Michael Smylie, professor of medical oncology at the University of Alberta. “All we’re doing [with immuno-oncology] is reversing that manipulation and activating the immune cells so the system will recognize the disease as ‘foreign’ and get rid of it.” In the past few years, this new approach to cancer treatment has been shown to dramatically improve the survival rates for certain cancers including small-cell lung cancer, melanoma, bladder cancer, and colorectal cancer. “It’s a revolution in cancer treatment,” Dr. Smylie says. Comparing cancer treatments By using the body’s immune system to find and destroy tumour cells, Dr. Smylie explains that the disease can be targeted more effectively than with conventional cancer treatments like chemotherapy. “When you give a patient chemotherapy, you hope that you’re lucky and that the chemotherapy kills enough cancer cells that the tumour will shrink down enough to make the patient feel better and hopefully improve their survival,” says Dr. Smylie. “However, there is a lot of toxicity involved with chemotherapy.” The side effects associated with immuno-oncology depend on the specific drug and dose administered, but this therapy may not be as hard on patients as other forms of cancer treatment. In addition, immunotherapy allows the immune system to spot cancerous cells that might otherwise be missed, thereby reducing the risk of recurrence. “Immune cells can find microscopic disease which imaging can’t detect and they can actually destroy the microscopic metastasis before they become apparent,” says Dr. Smylie, who has seen this process first hand with some of his melanoma patients. Positive prognosis Working in oncology can be tough, but Dr. Smylie says that this new “Immune cells can find microscopic disease which imaging can’t detect and they can actually destroy the microscopic metastasis before they become apparent.” form of treatment enables him to give even patients with advanced cancer some hope. “[Immune cells] are there to eradicate all cancer cells that they encounter so this treatment can potentially lead to longterm survivorship in Stage IV cancer patients who would have previously had a limited survival rate,” he says. Several of the patients who he diagnosed as terminally ill in 2007 — estimating that they had between six months to a year left — are still alive today and living cancer-free because of immunotherapy. Forbes called immuno-oncology “one of the hottest fields in biopharma today,” with ongoing research and numerous new treatments in development for various types of cancer. “We’re getting close,” says Dr. Smylie. “I think in the next five years, we’re going to see tremendous breakthroughs in cancer treatment.” After more than two decades working in oncology, Dr. Smylie says that the past few years have been the most exciting time in his practice because of immunotherapy. “It’s going to change the way we practice cancer medicine,” he says. THE HARD FACTS ABOUT LUNG CANCER IN CANADA #1 LUNG CANCER IS THE MOST COMMON CANCER, AND BY FAR THE LEADING KILLER OF ALL CANCERS IN CANADA EVERY DAY EVERY HOUR 57 57 CANADIANS WILL DIE FROM LUNG CANCER. THE FIVE-YEAR SURVIVAL RATE FOR LUNG CANCER IS ONLY 17% VS. 95% PROSTATE 88% BREAST 64% COLORECTAL 2 CANADIANS WILL BE LOST FOREVER TO THEIR FAMILIES, FRIENDS AND LOVED ONES. KILLS 20000+ CANADIANS EACH YEAR. MORE THAN BREAST, PROSTATE, AND COLON CANCER COMBINED. LUNG CANCER ACCOUNTS FOR 25% OF ALL CANCER DEATHS IN CANADA. ADVANCEMENTS ARE HANDICAPPED BY LUNG CANCER $ $ OTHER CANCERS VASTLY INADEQUATE RESEARCH FUNDING. THIS NEEDS TO CHANGE AND WE NEED YOUR HELP... DONATE / VOLUNTEER / ADVOCATE LEARN MORE AT LUNGCANCERCANADA.CA About Lung Cancer Canada Based in Toronto, Lung Cancer Canada (LCC) is Canada’s only national charitable organization that is solely focussed on lung cancer. Lung Cancer Canada serves as Canada’s leading resource for lung cancer education, patient support, research, and advocacy. LCC’s mission is four-fold: 1) to increase public awareness of lung cancer, 2) to support and advocate for lung cancer patients and their families, 3) to provide educational resources to patients, family members, healthcare professionals, and the general public, and 4) to raise funds in support of promising research opportunities. MEDIAPLANET 9 A sponsored feature by Mediaplanet INSPIRATION GENRE CATEGORY Photo: Roberto Aguilar Hair: Nick Irwin Makeup: Jenny Morrell Stylist: Marie Louise Von Haselberg Canadian Actress Emmanuelle Chriqui is Committed to Educating Canadians about Colon Cancer Canadian actress, Emmanuelle Chriqui, sits down with Mediaplanet to share her experience having lost both parents to colon cancer. Mediaplanet You’ve been a social advocate for colon cancer awareness for a number of years now. Can you tell us how colon cancer has affected you personally? Emmanuelle Chriqui My mother had colon cancer. It wasn’t her primary form of cancer, but the colon cancer is the part that I remember the most — only because she had a colostomy procedure. She lived with the pouch for five years. It was such a rotten thing. Everything in your system gets re-wired so to speak, and it’s not an easy adjustment. Obviously for the person who’s going through it, but also for the people living around it. So my mom was with the colostomy pouch for five years and then she got sick again. It was pretty awful to see. She was a fighter, but she suffered a lot. I had a hard time grasping the amount of suffering that was attached to her colon cancer. She passed away when I was 16, so my mom was sick for most of my growing up. And then much, much later, my father got colorectal cancer. He too had a colostomy and had to live with a pouch for about three years. And my poor dad, he just hated it. I don’t think he ever got used to it. He passed away four years ago. MP Did these experiences contribute to your desire to raise awareness about colon cancer? EC Yes, absolutely. It was a very organic de- cision for me, seeing as how both my parents suffered from colon cancer. I’m from Can- ada, but I haven’t lived in Canada for almost 16 years. So it was a very specific decision for me to want to be part of a Canadian organization that works to raise awareness about colon cancer — in memory of my parents. tory. And you know what? It’s super empowering to take your health into your own hands. It’s empowering and it’s necessary. Cancer does not equal death anymore. We can beat it now. MP You’re right — colon cancer is preventable in 90 percent of cases. How do you convince people to take that essential step of getting screened? EC By removing the shame attached to colon MP What kind of advice would you give to people in general who, at this point in their lives, are at risk for colorectal cancer, but haven’t taken steps to get screened? EC My advice is to look at your family history cancer and getting people to make their health a priority. The biggest thing that I always say — and this is probably because I’m somebody who’s lived through both my parents dying from colon cancer — is that people need to be more proactive about taking their health into their own hands. You need to have awareness about your own health — especially if you have a dicey family his- and take a proactive approach to your health. Make healthy choices — healthy lifestyle choices. We live in crazy times, but we also live in really exciting times. It’s possible to live healthily and to make conscious choices about what you put in your body. I think that making healthy lifestyle choices is really important, and they become more important as you get older. ss campaign urging Canadians to just “Get the Test.” The test could be as simple as an at-home procedure. For those with a family history of colon cancer or who are over 50, it might be more appropriate to undergo a colonoscopy. The WHO’s announcement has generated a public conversation on colon cancer — not an easy feat to accomplish — so let’s use the opportunity to encourage the choices that will really save lives: getting tested. That’s what the meat of the conversation should be. Amy Elmaleh Executive Director, Co-Founder of Colon Cancer Canada A Little “ick” Could Save Your Life Y ou’ve probably heard about the WHO’s announcement that processed meats like hot dogs and bacon are carcinogenic. This declaration resulted in a media outcry about having to give up our beloved prepared meats. It’s the wrong conversation to have about cancer, especially colon cancer. We should be talking about screening and prevention — that’s where we can make a difference. The Canadian Cancer Society states colon cancer is the second leading cause of death from cancer in men and the third leading cause in women. When detected early, colon cancer is 90 percent treatable, so that’s where our focus should be — on increasing uptake on screening. If we can encourage more Canadians to overcome the “ick” factor associated with colon cancer testing, we could dramatically reduce the devastation of this disease. Colon Cancer Canada launched an awarene- Are you at risk for Colorectal Cancer? R Early detection of colorectal cancer improves the chances of recovery and survival. A simple blood test can help determine your risk of colorectal cancer. Ask your healthcare provider about Cologic today. ® LifeLabs and the LifeLabs logo are registered trademarks of LifeLabs LP. © LifeLabs 2015. Cologic® is a registered trademark of LifeLabs LP. The Cologic® test is intended for use in risk assessment and monitoring; it is not a standalone test, and is not a screening test for colorectal cancer. Speak to your healthcare provider for more information. LifeLabs.com I 1-877-849-3637 I CologicLabTest.com @LifeLabs 10 CANCERCARENEWS.CA A sponsored feature by Mediaplanet INSPIRATION Radioembolization can destroy the tumour over several weeks, and reduce the risk of systemic side effects compared to other therapies. Cutting Edge Treatment Improves Prospects for Liver Cancer Patients I By Randi Druzin n October, iconic buildings throughout the United Kingdom were bathed in pink light. NFL players wore pink on their shoes during games across the U.S. and, in Canada, hundreds attended high-profile galas — all to increase awareness of breast cancer and raise money to treat it. While people across the Western world are aware of this disease and a handful of other cancers, liver cancer is not on their radar. But that may soon change. It is less prevalent here than in countries where chronic hepatitis B and C, leading causes of the disease, are more widespread. However, according to the Canadian Cancer Society Statistics 2015, incidence as well as mortality rates for liver cancer are on the rise. Surgical resection and liver transplantation are the best treatment options for liver cancer. However, surgery is not always possible due to the size of the cancer or it spreading to other parts of the body. Other options include, embolization, ablation, chemotherapy (often a drug called sorafenib), external bean radiation, and internal radiation therapy, which is also known as radioembolization. In a treatment known as embolization, a substance is put into the artery carrying blood to the tumour. This substance blocks the blood flow, which makes it harder for the tumour to grow and sometimes causes all or part of it to die. Ablation consists of inserting a needle or probe into the tumour and destroying it by delivering extreme heat, cold, or concentrated alcohol (ethanol). that there is a radioembolzation treatment manufactured in Ottawa that has already been used in over 19,000 patients worldwide. Many interventional radiologists have endorsed this procedure, citing its many benefits. “The treatment targets the tumour and leaves surrounding tissue unharmed. That means you can deliver radiation without killing the “In radioembolization a catheter is used to deliver small radioactive beads directly to the tumour in the liver.” Healthcare providers started adding a chemotherapy drug to embolization in the 1970s (chemoembolization) and, in the past decade, have been combining embolization with radiation treatment (radioembolization). In a radioembolization procedure, a catheter is used to deliver microscopic radioactive beads directly to the tumour in the liver. The beads, which are glass, become lodged in the tumour and, over the course of several weeks, emit radiation that can destroy it. Few people realize liver, something that would be very difficult to do otherwise,” says Dr. Richard Owen, an Interventional Radiologist and an Associate Professor in the Department of Radiology and Diagnostic Imaging at the University of Alberta in Edmonton. “In many instances patients have been too unwell to tolerate established treatments,” adds Dr. Sean Cleary, a surgeon at Toronto General Hospital, “so chemoembolization and radioembolization techniques have been considered because they can be delivered with fewer side effects and risks.” Radioembolization can be used to shrink large tumours down to the point where they can be surgically removed, and to treat tumours that are not responsive to other treatments. Dr. Rob Beecroft, an Interventional Radiologist at Princess Margaret Hospital in Toronto, says he has used the procedure to treat patients who would not have tolerated sorafenib because they were older and more fragile — he reports that it worked remarkably well. “In my opinion, in certain patients with advanced liver cancer, radioembolization can be more effective than sorafenib,” he says, “and have fewer side effects.” Side effects include fatigue, pain, and nausea. The majority of adverse effects are mild to moderate in severity and are manageable or resolve over time. Just as many healthcare providers have voiced their approval of this new therapy, they have expressed concern over its lack of availability. New treatment not funded for many Canadians Although the treatment is costly, it is less expensive than other liver cancer treatments and is publicly funded only in British Columbia and Alberta. It’s available in just six provinces — British Columbia, Alberta, Saskatchewan, Ontario, Nova Scotia, and Quebec. Many Canadian patients seeking the treatment have to go to the United States to get it, which often costs them tens of thousands of dollars. Qualifying patients may also opt for enrollment into radioembolization clinical trials available in Nova Scotia, British Columbia, Alberta, Quebec, and Ontario. More information on these trials can be found at www.btgplc.com. “For many patients radioembolization is clearly the best treatment,” says Owen. “However, for the majority of Canadians it’s just not available.” Dr. Owen would like to see this “made in Canada” treatment available in all major centres in conjunction with transplant programs. He says treatment would have to be overseen by a team of specialists from various disciplines. Without a doubt, more public funding would help the growing number of Canadians battling liver cancer. With established treatments improving and new treatments being developed, physicians will be able to target liver cancer with even more precision and greater success. An Army of Glass: The Remarkable Liver Cancer Treatment You Have Probably Never Heard Of When Eleanor Cook’s cancer spread to her liver, it was a sign that something in her treatment regimen had to change. Surgery and chemotherapy had already saved her life once since she was first diagnosed with cancer in 2013, but these new tumours would not be beaten by the same familiar tools. “I wasn’t a candidate for surgery because I had too many tumours on both sides of my liver,” Eleanor explains. “They couldn’t do a resection.” Her search for a treatment that could help sent her ranging across North America from her home in Fernie, British Columbia all the way to New York City before finally leading her to Dr. Richard Owen in the Department of Radiology and Diagnostic Imaging at the University of Alberta in Edmonton. Millions of tiny glass soldiers in the bloodstream Dr. Owen suggested to Eleanor that her cancer might respond well to a liver-targeted microsphere therapy. The treatment involves the injection of millions of tiny glass beads (each only a third the width of a human “I have hope now that I’m going to have more years to enjoy my family, my grandchildren, and doing the things I enjoy doing." Eleanor Cook (second from right) spending valuable time with her family. Photo: Submitted hair) directly into the artery of the liver, where the overdeveloped blood vessels of the tumours suck them up. Each bead contains a microscopic payload of yttrium-90, a radioactive isotope that can destroy the tumours from the inside while leaving healthy liver tissue largely unharmed. Eleanor has now undergone two separate treatments of microsphere therapy, the first targeting one half of her liver this past summer, and the second targeting the other half in Oc- tober. To her, one of the most miraculous aspects of the treatment was how easy, non-invasive, and painless it was. “It was nothing,” she says. “I was [at the University of Alberta Hospital] just for the day, spent one night in Edmonton, and was back home the next day. The only side effect I experienced was a little bit of fatigue. The care and compassion at the hospital was just incredible. From the time I arrived until I was discharged, they treated me extremely well.” Canadians dying from lack of access and awareness Since its invention, this microsphere technology has been used worldwide to provide hope to thousands of patients like Eleanor with inoperable liver cancer. In Canada, however, the treatment is arguably underutilised, with a lack of awareness and funding preventing oncologists from recommending it to patients whose lives it could potentially save. Eleanor believes she would never have even heard of the treatment if she had not been proactive in reaching out to Dr. Owen of her own accord. It’s understandable, of course, that it takes time for new therapies to receive funding, and that doctors are slow to change the treatment plans that have been working for them. At the same time, Canadians living with cancer deserve to have the best treatments available to them, and they have a right to be fully informed about their options. For Eleanor, receiving this treatment has had a profound effect on her outlook for the future. “I have hope now that I’m going to have more years to enjoy my family, my grandchildren, and doing the things I enjoy doing,” she says. “It’s given me a lot of hope and I was extremely fortunate to be able to have the procedure done.” Hopefully soon all Canadians with this disease will have the opportunity to be so fortunate. By D.F. McCourt MEDIAPLANET 11 Commercial Feature FACTS It is estimated that... Liver cancer will account for 2.1% of cancer deaths in Canada 2 in 5 Canadians will develop cancer in their lifetimes 275,200 new cases of cancer will be diagnosed in 2015 2,200 Canadians will be diagnosed with liver cancer in 2015 78,000 Canadians will die of cancer in 2015 1,100 Canadians will die from liver cancer in 2015 Source: Canadian Cancer Statistics 2015, Canadian Cancer Society Liver Cancer is on the Rise in Canada: Access Treatment is Critical Don’t to let liver cancer go unnoticed. Undiagnosed liver disease can lead to liver cancer. Livermay cancer can often be treatedfor — and cured — you if caught early. of. There be treatment options livereven cancer that are unaware Talk to yourbeen doctorshown about liver at youreffective next appointment. New targeted therapies have totests be very in treating liver tumours but more information, call our Help Line at 1-800-563-5483, emailthese clf@liver.ca or visit liver.ca may beForunder-utilized in Canada. Ask your doctor about therapeutic options today. Research | Education | Patient Support | Advocacy Sponsored by Don’t let liver cancer go unnoticed. Undiagnosed liver disease can lead to liver cancer. Liver cancer can often be treated — and even cured — if caught early. Talk to your doctor about liver tests at your next appointment. For more information, call our Help Line at 1-800-563-5483, email clf@liver.ca or visit liver.ca Research | Education | Patient Support | Advocacy 12 PERSONALHEALTHNEWS.CA A sponsored feature by Mediaplanet NEWS Knowing Your Options Post-Mastectomy Raising awareness about breast reconstruction in Canada. For most women, being diagnosed with breast cancer can trigger a complex spectrum of physical and emotional reactions that go well beyond obvious health concerns. Breasts are not only part of the female sexual identity but they are often inextricably linked to a woman’s very sense of self. Thanks to an array of educational campaigns and events over the past decade, breast cancer awareness continues to increase. Much less well-known, unfortunately, are a woman’s options regarding breast reconstruction. This lack of awareness affects not just breast cancer survivors who have undergone mastectomies, but also those who have elected to have the procedure because they have a family history or carry the genetic marker for the disease. Toronto plastic surgeon Doctor Mitch Brown is all too aware of cancer survivors’ lack of information about their options. So passionate is his belief in the issue, that in 2011 he founded Breast Reconstruction Awareness (BRA) Day. “BRA is based on the idea that women in Canada and throughout the world don’t have a full understanding of the opportunity for breast reconstruction,” says Dr. Brown. Dr. Brown emphasizes that, though breast reconstruction is an individual choice and may not be right for all women, it’s an important issue because, “…for those who are candidates for the procedure, it can Doctor Mitchell Brown Associate Professor, Department of Surgery, University of Toronto have a significant positive impact on their quality of life.” Immediate breast reconstruction Of special interest for mastectomy patients is the growing popularity of immediate breast reconstruction. “Immediate breast reconstruction is when reconstruction is either started or done completely at the same time as a mastectomy,” explains Doctor Peter Lennox, a Vancouver-based plastic surgeon. This option is significant because it allows patients to spend less time in surgery. “The goal is to reduce the number of operative procedures a person requires in an effort to help reduce the emotional or psychological impact of having a mastectomy and hopefully to give the patient a better outcome,” says Dr. Lennox. Dr. Lennox also notes that awareness and access to immediate breast reconstruction surgery is dependent on where one lives in Canada. Doctor Peter Lennox Head, Division of Plastic Surgery, University of British Columbia In Vancouver, mastectomy patients are routinely informed about the surgical option. He also points out that the ideal candidate for immediate breast reconstruction likewise varies; noting that some plastic surgeons believe the majority of mastectomy patients would be eligible for the procedure. In Dr. Brown’s opinion, however, the best candidates for immediate breast reconstruction, are “…women who’ve had preventative mastectomies…or those where the cancer was detected at an early stage so there is a low likelihood of chemotherapy or radiation after the mastectomy.” What isn’t dependent on where one lives in Canada, however, is the cost of breast reconstruction surgery. The procedure is a medical service that is completely covered under each province’s health care plan. More than By Sandra MacGregor A COMMERCIAL FEATURE BY LIFECELL™ AN ACELITY COMPANY THE FUTURE OF BREAST RECONSTRUCTION Innovative medical techniques and technology promise to revolutionize post-mastectomy breast reconstruction. W hile society’s understanding of breast cancer continues to develop, thanks to a variety of educational campaigns, there has been a growing increase in the medical community’s awareness of the options and technologies designed to help women deal with some of the physical after effects of the disease. Some of the most significant progress — both in awareness and in technology — is in the area of breast reconstruction after a mastectomy. “A field that has seen a great deal of advancement,” explains Doctor Peter Lennox, a Vancouver-based plastic surgeon, “is immediate breast reconstruction, which is when breast reconstruction is either started or done completely at the same time as a mastectomy.” Toronto plastic surgeon Doctor Mitch Brown would agree, “There have been improvements in tech- Women gather at BRA Day events across the country to share their journeys and help raise awareness about breast reconstruction. Photo: Willow Breast & Hereditary Cancer Support nology available for plastic surgeons to provide good results in immediate breast reconstruction. Some of those advances have been medical devices and breast implant technology, as well as the materials we use as internal tissue support structures known as acellular dermal matrices (ADM).” Dr. Lennox is equally as enthusiastic about developments in ADMs. “Acellular dermal matrices — of which AlloDerm® Regenerative Tissue Matrix falls into this category — can help promote good outcomes in breast reconstruction surgery… because it becomes incorporated into the patient’s own tissue and acts as support where soft tissue exists.” He also notes that another advantage of ADMs is that they allow direct-to-implant reconstruction, which hadn’t been possible before. “Implant reconstruction used to involve two stages. A tissue expander was used to help shape the skin and then you would go back to the operating room a few months later to add a permanent implant. With dermal matrices and the right candidate, we can skip that step and, at the same time as a mastectomy, go directly to putting in a breast implant. Thanks to ADMs, everything can be done in one operation.” One ADM that sets itself apart from others is AlloDerm® RTM. Doctor John Harper, PhD, SVP Chief Technology Officer at LifeCell, explains “AlloDerm® RTM works by gradually integrating into the pa- Only 3 out of 10 women are offered breast reconstruction.* At LifeCell, we believe that’s 7 women too few. To learn more, visit www.lifecellcorp.ca *Alderman, A. K. et al. Understanding the Impact of Breast Reconstruction on the Surgical Decision-Making Process for Breast Cancer. Cancer 2008 © 2015 LifeCell Corporation. All rights reserved. LifeCell™ is a trademark of LifeCell Corporation. MLC4698-CA/5125/10-2015 tient. As the body grows into AlloDerm® RTM, new tissue is regenerated that doesn’t have the disadvantages of scar tissue. To produce AlloDerm® RTM, donor tissue cells are removed from the human skin through the LifeCell proprietary processing methods. This prevents it from rejection by the normal transplantation reaction; instead allows it to be accepted as though it were the patient’s own tissue.” Dr. Lennox also points out that there have also been exciting advancements in fat grafting and breast reconstruction. “You can inject a patient’s fat into different layers of tissue to build up a network of fat cells in the tissue left behind. This allows you to improve the thickness of the mastectomy flap or add the fat tissue to the pectoral muscles to get more volume and improve breast contour and asymmetries. It can really improve the quality of the reconstruction.”